Introductory Chapter: The Global Distribution of Human Histoplasmosis - An Overview

Bongomin, Felix; Nsenga, Lauryn

doi:10.5772/intechopen.92981

Cited by 1 publication

(1 citation statement)

References 49 publications

(95 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathology reveals yeast in tissue samples but sensitivity is variable [ 63 ]. Fungal culture from blood or bronchoalveolar lavage is the gold standard; however, the fastidious organism requires a biosafety level (BSL)-3 laboratory, thus limiting widespread implementation [ 64 ]. Serologic testing, while easier to perform in the laboratory, has inadequate sensitivity (58%) compared to culture [ 65 ].…”

Section: Ahd-associated Opportunistic Infectionsmentioning

confidence: 99%

Advanced HIV disease: A review of diagnostic and prophylactic strategies

et al. 2023

View full text Add to dashboard Cite

Background Despite expanded access to antiretroviral therapy (ART) and the rollout of the World Health Organization's (WHO) ‘test‐and‐treat’ strategy, the proportion of people with HIV (PWH) presenting with advanced HIV disease (AHD) remains unchanged at approximately 30%. Fifty percent of persons with AHD report prior engagement to care. ART failure and insufficient retention in HIV care are major causes of AHD. People living with AHD are at high risk for opportunistic infections and death. In 2017, the WHO published guidelines for the management of AHD that included a comprehensive package of care for screening and prophylaxis of major opportunistic infections (OIs). In the interim, ART regimens have evolved: integrase inhibitors are first‐line therapy globally, and the diagnostic landscape is evolving. The objective of this review is to highlight novel point‐of‐care (POC) diagnostics and treatment strategies that can facilitate OI screening and prophylaxis for persons with AHD. Methods We reviewed the WHO guidelines for recommendations for persons with AHD. We summarized the scientific literature on current and emerging diagnostics, along with emerging treatment strategies for persons with AHD. We also highlight the key research and implementation gaps together with potential solutions. Results While POC CD4 testing is being rolled out in order to identify persons with AHD, this alone is insufficient; implementation of the Visitect CD4 platform has been challenging given operational and test interpretation issues. Numerous non‐sputum POC TB diagnostics are being evaluated, many with limited sensitivity. Though imperfect, these tests are designed to provide rapid results (within hours) and are relatively affordable for resource‐poor settings. While novel POC diagnostics are being developed for cryptococcal infection, histoplasmosis and talaromycosis, implementation science studies are urgently needed to understand the clinical benefit of these tests in the routine care. Conclusions Despite progress with HIV treatment and prevention, a persistent 20%–30% of PWH present to care with AHD. Unfortunately, these persons with AHD continue to carry the burden of HIV‐related morbidity and mortality. Investment in the development of additional POC or near‐bedside CD4 platforms is urgently needed. Implementation of POC diagnostics theoretically could improve HIV retention in care and thereby reduce mortality by overcoming delays in laboratory testing and providing patients and healthcare workers with timely same‐day results. However, in real‐world scenarios, people with AHD have multiple comorbidities and imperfect follow‐up. Pragmatic clinical trials are needed to understand whether these POC diagnostics can facilitate timely diagnosis and treatment, thereby improving clinical outcomes such as HIV retention in care.

show abstract

Section: Ahd-associated Opportunistic Infectionsmentioning

confidence: 99%